Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 6/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27933710 | 0.89 | GABRA5 (0.37) | GABRA5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9894488 | 0.88 | GABRA5 (0.43) | GABRA5GRM1PSEN1PSEN2APH1B | |
| SCHEMBL9895487 | 0.87 | MAPK14 (0.43) | GABRA5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9894928 | 0.86 | MAPK14 (0.47) | MAPK14PTGER4MAP4K4TNIKCSNK1D | |
| SCHEMBL9894845 | 0.86 | MAP4K4 (0.41) | GABRA5GRM1PSEN1PSEN2APH1B | |
| SCHEMBL9895019 | 0.85 | MAP4K4 (0.53) | MAPK14MAP4K4TNIKCSNK1D | |
| SCHEMBL27933718 | 0.83 | MAPK1 (0.35) | GABRA5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9895619 | 0.82 | GABRA5 (0.47) | GABRA5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6468600 | 0.82 | GABRA5 (0.49) | GABRA5GRM1PTGER4CSNK1D | |
| SCHEMBL9894672 | 0.82 | GABRA5 (0.55) | GABRA5HPGDCSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | claimed |
| EP-2649064-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. Hoffmann-La Roche AG (CH) | 2013-10-16 | — | — | EP | claimed |
| CN-103249728-A | Novel triazole compounds III | HOFFMANN LA ROCHE | 2013-08-14 | — | — | CN | claimed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | claimed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | claimed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | claimed |
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | disclosed |
| EP-2649064-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. Hoffmann-La Roche AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| CN-103249728-A | Novel triazole compounds III | HOFFMANN LA ROCHE | 2013-08-14 | — | — | CN | disclosed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | disclosed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | disclosed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | GABRA5, GABRA1, GABRB1 | GABRA5 1/4885GRM1 112/4885PSEN1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.